Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
November 14 2016 - 8:00AM
- Emricasan Improves Liver Function in
Cirrhosis Patients with NASH and/or Elevated MELD Scores
-
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the
presentation of four posters – two addressing clinical results and
two addressing preclinical results with the company’s pan-caspase
inhibitor, emricasan – at The Liver Meeting®, the annual meeting of
the American Association for the Study of Liver Diseases (AASLD) in
Boston November 11-15, 2016.
Poster #2095, “Emricasan (IDN-6556) Orally for 6 Months in
Patients with Cirrhosis and Elevated MELD Score Improves Liver
Function,” will be presented by Catherine Frenette, M.D., Medical
Director of Liver Transplantation at Scripps Clinic, La Jolla, CA,
and a principal investigator in the company’s multicenter Phase 2
Liver Cirrhosis clinical trial of emricasan.
Poster #2099, “Emricasan (IDN-6556) Orally for 6 Months in
Patients with Non-alcoholic Steatohepatitis (NASH) Cirrhosis
Decreases the Progression of MELD Score and Improves Liver
Function,” also will be presented by Dr. Frenette.
“We were highly encouraged by the results from our Phase 2 Liver
Cirrhosis trial after the first three months of treatment, which
showed improvement using two clinically relevant measures of liver
function and prognosis – MELD and Child Pugh scores – in the high
baseline MELD score subgroup, and decreased progression using the
same two measures in the NASH subgroup regardless of baseline MELD
score,” said David T. Hagerty, M.D., Executive Vice President of
Clinical Development at Conatus. “The continued directional
improvements after six months of treatment support continued
development in patients with NASH cirrhosis, and directly inform
the design of our upcoming ENCORE-LF trial.”
Poster #2097, “The pan caspase inhibitor Emricasan improves the
hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading
to portal hypertension amelioration and cirrhosis regression,” will
be presented by Jordi Gracia-Sancho, Ph.D., Ramón y Cajal
Researcher in Biomedicine at Barcelona Hepatic Hemodynamic Lab,
IDIBAPS Biomedical Research Institute & CIBEREHD, Barcelona,
Spain.
Poster #2098, “Circulating microparticles carry apoptosis
markers CK-18 and caspase-3/7 which are reduced by treatment with
Emricasan in subjects with chronic liver diseases,” will be
presented by Akiko Eguchi, Ph.D., Project Scientist in the
Department of Pediatrics, University of California San Diego, La
Jolla, CA.
“Thanks to the continuing efforts of our independent research
collaborators, we continue to expand our understanding of
emricasan’s multiple mechanisms of action,” said Alfred P. Spada,
Ph.D., Executive Vice President of Research and Development and
Chief Scientific Officer of Conatus. “The cirrhotic rat portal
hypertension study demonstrated that emricasan improved
microvascular dysfunction in the liver and drove related
improvements in fibrosis, portal hypertension and liver function.
The detailed analysis of serum samples from our hepatic impairment
trial showed that subjects with severe hepatic injury have elevated
levels of circulating microparticle-encapsulated cCK-18 and active
caspase-3/7, and that emricasan can reduce these elevated levels.
These results support continued development in patients with NASH
cirrhosis.”
Both poster #2095 and poster #2097 were accepted as
“Presidential Posters of Distinction,” indicating review scores
that place them within the top 10 percent of all posters
submitted.
All four posters will be displayed in Hall C on Level 2 of the
Hynes Convention Center in Poster Session IV on Monday, November
14, from 8:00 a.m. to 5:30 p.m. EST, with authors available for
discussion at the posters from 12:30 p.m. to 2:00 p.m. EST. Copies
of the posters are available in the Data section of the Conatus
website at www.conatuspharma.com.
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease.
Conatus is developing its lead compound, emricasan, for the
treatment of patients with chronic liver disease. Emricasan is a
first-in-class, orally active pan-caspase inhibitor designed to
reduce the activity of enzymes that mediate inflammation and
apoptosis. Conatus believes that by reducing the activity of these
enzymes, emricasan has the potential to interrupt the disease
progression across the spectrum of liver disease. For additional
information, please visit www.conatuspharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward looking statements, including
statements regarding: the Liver Cirrhosis trial results and
preclinical results as support for continued development of
emricasan in patients with NASH cirrhosis; and emricasan’s
potential to reduce caspase activity and interrupt disease
progression across the spectrum of liver disease. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative
of these terms or other similar expressions. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions,
including: Conatus’ ability to initiate and successfully complete
current and future clinical trials; the risk that the preclinical
results may not be predictive of future clinical results; the
uncertainty of the U.S. Food and Drug Administration’s and other
regulatory agencies’ approval processes and other regulatory
requirements; and those risks described in Conatus’ prior press
releases and in the periodic reports it files with the Securities
and Exchange Commission. The events and circumstances
reflected in Conatus’ forward-looking statements may not be
achieved or occur and actual results could differ materially from
those projected in the forward-looking statements. Except as
required by applicable law, Conatus does not plan to publicly
update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed
circumstances or otherwise.
MEDIA: David Schull
Russo Partners, LLC
(858) 717-2310
David.Schull@RussoPartnersLLC.com
INVESTORS: Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2023 to Apr 2024